remov epacadostat slash
follow failur ido melanoma manag confer call
remov ido indic model sharpli discount
post-ido pipelin lower pt point
underli valu could see neg news associ ido
readout uncertainti remain around next late stage candid
believ stock attract posit trade valuat
commerci drug jakafi olumi minim pipelin valu
consequ revis model reiter buy
miss endpoint neg read
epacadostat indic today announc trial
epacadostat keytruda metastat melanoma achiev statist
signific co-primari endpoint expect achiev
signific co-primari endpoint os hazard ratio
ci os immatur event
reach hazard ratio ci trial halt
recommend extern data monitor committe data
studi analyz present upcom scientif confer
extens biomark panel trial analyz base
hazard ratio believ unlik find subgroup
trial success current incyt phase trial underway
epacadostat nsclc bladder rcc scchn believ
melanoma one promis indic neg
result signific read indic remov
epacadostat indic model reduc valu
pt also trim sg spend
near term await clariti spend earn
model chang remov epacadostat
model
consequ probabl adjust peak sale decreas
also trim pipelin valu take
initi conserv stanc await next lead pipelin asset
emerg lower pt varianc tabl
stock trade less valu jakafi olumi solid
foundat asset remain buy view near term
catalyst strong earli pipelin remov epacadostat
model major valuat come jakafi/jakavi jakafi
sale year myelofibrosi polycythemia vera
also potenti label expans gvhd expect result
pivot phase trial steroid refractori gvhd jakafi
tr target
repres pt addit near term catalyst olumi olumi face
adcom april rheumatoid arthriti olumi would commerci
buy john bori entitl tier royalti sale lilli also state
result phase trial olumi system lupu erythematosu expect
present medic meet later olumi repres pt
target pipelin includ promis asset one advanc
pipelin asset delta inhibitor phase trial multipl hematolog
tumor class well establish may best class molecul dose
scheme includ plan dose reduct could overcom toler issu common
class see note capmatinib inhibitor licens
novarti nv rate current phase trial patient met-amplifi lung
cancer data expect novarti state anticip submit nda
indic
immun oncolog pipelin includ gitr expect phase clinic
data gitr program medic confer
howev given ido failur caution near term io agent
shown singl agent activ also see
preclin data april
catalyst focu molecul pivot phase trial result jakafi
steroid refractori agvhd like olumi adcom fda decis data
gitr molecul next month
valuat dcf/npv valuat use probabl adjust peak sale
discount rate probabl success yield pt jakafi mf pv
gvhd olumi epacadostat melanoma solid tumor
cash/technolog bull/bear case model yield pt risk includ competit
impact jakafi olumi uptak
page
data catalyst next month highlight
page
candidatetargettim mileston settingpartnerepacadostat durvalumab data solid tumorsio data pair biopsi trial multipl tumor typesepacadostat keytruda updatesolid tumorsepacadostat opdivo updatesolid datasolid datasolid tumorsruxolitnib phase resultssteroid refrectori initi pivot programpsoriat arthritis decisionrheumatoid arthritis glioblastoma liver cancer incyt corpor
page
 epacadostat- jakavi olumiant- mileston revenues- adjust sale probabl success weight weight technolog incyt corpor
page
page
quarterli sale royaltiesjakafi jakafi gvhd/transplant- iclusig cml- product olumi ra us- ra row- fair valu acquisit incom incom incom ep product ep inc stock share outstand corpor
page
annual jakafi gvhd/transplant- epacadostat melanoma- epacadostat solid tumor- iclusig cml- total product total fair valu acquisit incom interest incom incom ep inc stock share outstand corpor
commerci stage biotech compani believ gener signific cash flow
two partner asset develop deep pipelin oncolog asset incyt commerci asset jakafi
could see upsid addit indic fulli partner arthriti molecul olumi
launch would help fund well posit immuno-oncolog target
jakafi above-p biotech growth addit upsid new indic jakafi rapidli
grow drug myelofibrosi polycythemia vera project revenu
jakafi drug show durabl effect clinic benefit importantli jakafi
also shown encourag clinic benefit graft vs host diseas project peak
sale additoin valu come baricitinib non-oncolog rheumatoid arthriti ra focus cash
valuat risk
dcf/npv valuat use probabl adjust peak sale discount rate
probabl success yield pt jakafi mf pv gvhd
olumi epacadostat melanoma solid tumor cash/
technolog bull/bear case model yield pt risk rate price target includ
competit impact jakafi olumi uptak
compani mention note
compani buy john bori
novarti nv rate
peter lawson herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
